Programme
Annual Conference Agenda 2012 PDF (384 KB)"Clinical Trials - the current situation and future chances in the limelight"
Working towards better definition of outcome parameters covering individual responses in
sub-phenotypes
Monday 27th February
SESSION 1 - chaired by Prof. Torsten Zuberbier and Prof. Sergio Bonini
10.00 - 10.05
Welcome and opening remarks. Introduction of GA²LEN and the aims of the conference
Prof. Torsten Zuberbier, GA²LEN Secretary General
10.05 - 10.25
The future role of GA²LEN and its new position in the EU
Prof. Bolesław Samoliński, GA²LEN Vice President
Prof. Bolesław Samoliński, GA²LEN Vice President
10.25 – 10.40
GA²LEN view - current status and unmet needs in allergy, therapeutics & diagnostics
Prof. Sergio Bonini, Head of GA²LEN Clinical Trials group
Prof. Sergio Bonini, Head of GA²LEN Clinical Trials group
10.40 - 10.55
Manufacturers view - current situation and unmet needs
Lars Jacobsen, EAMG
Lars Jacobsen, EAMG
10.55 - 11.15
Coffee break
11.15 - 11.45
View of the EMA - current status and unmet needs in allergy trials and clinical care
Prof. Guido Rasi - Executive Director of the EMA
Prof. Guido Rasi - Executive Director of the EMA
11.45 - 12.30
Panel discussion among the mornings speakers
"Defining the unmet needs"
moderated by Prof. Sergio Bonini
moderated by Prof. Sergio Bonini
12.30 - 13.15
Lunch break / press conference and networking
SESSION 2 - chaired by Prof. Marcus Maurer and Prof. Jean Bousquet
13.15 - 13.30
Examples of methodology and gaps in rare allergic diseases including rare sub-types of allergic diseases "Schnitzler Syndrome"
Dr. Anna Simon, Raboud University Nijmegen Medical Centre
Dr. Anna Simon, Raboud University Nijmegen Medical Centre
13.30 - 13.45
Fourth level treatment options in urticaria
Prof. Marcus Maurer
Prof. Marcus Maurer
13.45 - 14.10
Hereditary angioedema and recurrent non-hereditary angioedema.
How to devise trials for unpredictable recurrent diseases
Prof. Bruce Zuraw, University of California, San Diego
How to devise trials for unpredictable recurrent diseases
Prof. Bruce Zuraw, University of California, San Diego
Airways Allergies
14.10 - 14.25
The Patients View - current status in unmet needs in allergy therapeutics and diagnostics, including ethics of placebo controlled trials
Frans Timmermans, Representative of EFA
Frans Timmermans, Representative of EFA
14.25 - 14.40
Pediatric patients - Special needs
Prof. Kai-Håkon Carlsen, GA²LEN Partner
Prof. Kai-Håkon Carlsen, GA²LEN Partner
14.40 - 15.00
Coffee break
SESSION 3 - chaired by Prof. Boleslaw Samolinski and Prof. Karin C. Lødrup Carlsen
Filling the gaps - new possibilities in the design of clinical trials and statistical analysis
15.00 - 15.15
Novel ideas in design and statistical variation - comments from a GA²LEN collaborating CRO
Dirk Reitsma, VP Product Development, PPD
Dirk Reitsma, VP Product Development, PPD
15.15 - 15.40
Novel ideas and possibilities in using smart phone technologies in GA²LEN projects
Prof. Jean Bousquet, GA²LEN Vice President
Prof. Jean Bousquet, GA²LEN Vice President
15.40 - 17.00
Open discussion with todays speakers and drafting the cornerstones of the conference declaration
moderated by Prof. Sergio Bonini
moderated by Prof. Sergio Bonini
18.30
Evening reception "Hörsaalruine" -
In the original lecture hall of Rudolf Virchow, one of the founding fathers of modern medicine. The ruins have eloquent room structure & historical, atmospheric charm.
Tuesday 28th February
SESSION 4 - chaired by Dr. Karsten Weller and Dr. Angelos Neou
Unpublished results of GA²LEN projects and novel GA²LEN projects
09.30 - 10.30
Results from GA²LENs Children - PreDicta and MeDALL
Nutritional components of the GA²LEN Programme, Dr. Vanessa Larsen
GA²LEN Reports and data - Prof. Peter Burney
Skin Prick Test Follow up study - ready to launch for March 2012 Dr. Karsten Weller, GA²LEN Integration Officer
Nutritional components of the GA²LEN Programme, Dr. Vanessa Larsen
GA²LEN Reports and data - Prof. Peter Burney
Skin Prick Test Follow up study - ready to launch for March 2012 Dr. Karsten Weller, GA²LEN Integration Officer
Coffee break / Q&A with Dr. Karsten Weller about the Skin Prick Test Follow-Up Study
10.30 - 11.00
13.02.2012
